These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 11934772)
1. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. Trotter CL; Edmunds WJ BMJ; 2002 Apr; 324(7341):809. PubMed ID: 11934772 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE; Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028 [TBL] [Abstract][Full Text] [Related]
3. Estimating the burden of serogroup C meningococcal disease in England and Wales. Davison KL; Ramsay ME; Crowcroft NS; Lieftucht A; Kaczmarski EB; Trotter CL; Gungabissoon U; Begg NT Commun Dis Public Health; 2002 Sep; 5(3):213-9. PubMed ID: 12434691 [TBL] [Abstract][Full Text] [Related]
4. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE; Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206 [TBL] [Abstract][Full Text] [Related]
5. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Trotter CL; Ramsay ME; Kaczmarski EB Commun Dis Public Health; 2002 Sep; 5(3):220-5. PubMed ID: 12434692 [TBL] [Abstract][Full Text] [Related]
6. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695 [TBL] [Abstract][Full Text] [Related]
7. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents. Si S; Zomer E; Fletcher S; Lee J; Liew D Vaccine; 2019 Aug; 37(35):5009-5015. PubMed ID: 31301916 [TBL] [Abstract][Full Text] [Related]
9. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands. Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135 [TBL] [Abstract][Full Text] [Related]
10. Economic evaluation on meningococcal vaccination strategies among children under nine years of age in Zhejiang province, China. Shen J; Ji C; Luo X; Hu Y PLoS One; 2024; 19(9):e0310274. PubMed ID: 39250492 [TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695 [TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study. Yaesoubi R; Trotter C; Colijn C; Yaesoubi M; Colombini A; Resch S; Kristiansen PA; LaForce FM; Cohen T PLoS Med; 2018 Jan; 15(1):e1002495. PubMed ID: 29364884 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of a universal infant immunization program with meningococcal C conjugate vaccine in Brazil. de Soarez PC; Sartori AM; de Andrade Lagoa Nóbrega L; Itria A; Novaes HM Value Health; 2011 Dec; 14(8):1019-27. PubMed ID: 22152170 [TBL] [Abstract][Full Text] [Related]
14. Meningococcal C vaccines: the Canadian experience. De Wals P Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070 [TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732 [TBL] [Abstract][Full Text] [Related]
16. Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England. Ladhani SN; Andrews N; Parikh SR; Campbell H; White J; Edelstein M; Bai X; Lucidarme J; Borrow R; Ramsay ME N Engl J Med; 2020 Jan; 382(4):309-317. PubMed ID: 31971676 [TBL] [Abstract][Full Text] [Related]
17. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Trotter CL; Edmunds WJ Med Decis Making; 2006; 26(1):38-47. PubMed ID: 16495199 [TBL] [Abstract][Full Text] [Related]
18. The costs associated with the public health management of a cluster of meningococcal infection in England. Letouze D; Yao G; Clarke SC Vaccine; 2014 Sep; 32(43):5549-51. PubMed ID: 25173479 [TBL] [Abstract][Full Text] [Related]
19. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany. Christensen H; Irving T; Koch J; Trotter CL; Ultsch B; Weidemann F; Wichmann O; Hellenbrand W Vaccine; 2016 Jun; 34(29):3412-9. PubMed ID: 27109566 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Melegaro A; Edmunds WJ Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]